Brian has been working with Elm Street Ventures and its portfolio companies since 2006. He has been the initial President and CEO of three ESV portfolio companies, all Yale spinouts: BioRelix, Osmol Therapeutics, and Stradefy Biosciences. Brian has been active in the New Haven area biotech community since joining Bayer in 1993. While a scientist there, he directed drug discovery efforts in both the Osteoporosis and Oncology therapeutic areas, where his research groups advanced a number of drug candidates into development. As a Bayer HealthCare Vice President he led a multi-disciplinary organization that delivered state-of-the-art expertise in oncology biomarker discovery, new lead discovery, research drug formulation, pharmacokinetics and drug metabolism to the company’s global R&D business. In addition, he held leadership roles in R&D licensing initiatives, strategic alliances and cross divisional collaborations in translational medicine. After Bayer, in addition to his roles as CEO and as an ESV Venture Partner, Brian has been advising founders, investors and companies in the biotechnology space.

Dr. Dixon was an undergraduate at the University of Michigan, received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and completed post-doctoral training at Harvard University in the labs of Nobel Laureate Elias J. Corey.